

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/825,282	
			Filing Date	April 14, 2004	
			First Named Inventor	Donald Bellgrau	
			Art Unit	1633	
			Examiner Name	Sumesh Kaushal	
Sheet	1	of	3	Attorney Docket Number	3921-1-1-1-1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5109580	05/05/92	Blanco et al.	
	2	5183058	02/02/93	Janese	
	3	5759536	06/02/98	Bellgrau et al.	
	4	6325999	12/04/01	Bellgrau et al.	
	5	08/250478		Bellgrau et al. (05/27/94)	
	6	09/456357		Bellgrau et al. (12/8/99)	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ^{5 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	7	WO 95/13293	05/18/95	Mochida Pharm Co LTD		(translated abstract)
	8	WO 99/13073	03/18/99	RPR Gencell Asia Pacific Inc.		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. ¹	
	9	Anderson, W. French , Human Gene Therapy, Nature Vol 392, Supp, April 30, 1998
	10	Friedmann, Theodore , Principles for Human Gene Therapy Studies, Vol 287, March 2000

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,282
				Filing Date	April 14, 2004
				First Named Inventor	Donald Bellgrau
				Art Unit	1633
				Examiner Name	Sumesh Kaushal
Sheet	2	of	3	Attorney Docket Number	3921-1-1-1-1

	11	Johnstone & Thorpe, "Immunochemistry in Practice", by Blackwell Scientific Publications, Oxford, (1987) pp. 30-47
	12	Lynch, et al., "Fas and FasL in the homeostatic regulation of immune responses, "Immunology Today, vol. 16, no. 12, December 1995, pages 569-574
	13	MOUNTZ, "Autoimmune disease," Arthritis & Rheumatism, vol. 37, no. 10, October 1994, pages 1415-1420
	14	Nagata et al. "The Fas Death Factor," (1995) Science 267:1449-1456
	15	Nagata, "Fas and Fas Ligand: A Death factor and its receptor," Adv. Immunol. Vol. 57, 1994, pages 129-144
	16	Nagata, Shigekazu et al, The Fas Death Factor, Science, Volume 267, March 10, 1995, pages 1449-1456
	17	SMITH et al., "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death," Cell, Vol. 76, 959-962, March 25, 1994
	18	Suda & Nagata, "Purification and Characterization of the Fas-ligand that induces Apoptosis," J. Exp. Med. Vol. 179, March 1994, pages 873-879
	19	Varmus, Harold , Gene therapy: Not ready for prime time, Nature Medicine, Volume 2, January 1, 1996
	20	Verma, Inder M. et al, Gene therapy promises, problems and prospects, Nature Vol 389, September 18, 1997
	21	Verma, Inder M. , "Gene Therapy: beyond 2000," Molecular Therapy Vol. 1, No.6, June 2000
	22	Notice of Reasons for Rejections for Japanese Application No. 08-501092, dated November 25, 2005 (Attorney's Reference No. 2848-20-PJP)
	23	Notice of Reasons for Rejections for Japanese Application No. 08-501092, dated September 26, 2006 (Attorney's Reference No. 2848-20-PJP)
	24	Decision to Grant a Patent for Japanese Patent Application No. Hei 8-501092, dated March 23, 2007 (Attorney's Reference No. 2848-20-PJP)
	25	Official Action for European Application No. 95921459.4, dated June 5, 2003 (Attorney's Reference No. 3921-1-PEP)
	26	Official Action for European Application No. 95921459.4, dated February 17, 2004 (Attorney's Reference No. 3921-1-PEP)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,282
				Filing Date	April 14, 2004
				First Named Inventor	Donald Bellgrau
				Art Unit	1633
				Examiner Name	Sumesh Kaushal
Sheet	3	of	3	Attorney Docket Number	3921-1-1-1-1

	27	Official Action for European Application No. 95921459.4, dated February 10, 2006 (Attorney's Reference No. 3921-1-PEP)
	28	Official Action for Canadian Patent Application No. 2,189,778, dated September 25, 2009 (Attorney's Reference No. 3921-1-PCA)
	29	Official Action for Canadian Patent Application No. 2,189,778, dated January 3, 2008 (Attorney's Reference No. 3921-1-PCA)
	30	Official Action for Australian Patent Application No. 26535/95, dated January 2, 1998 (Attorney's Reference No. 3921-1-PAU)
	31	Official Action for Australian Patent Application No. 26535/95, dated May 27, 1999 (Attorney's Reference No. 3921-1-PAU)
	32	Notice of Acceptance for Australian Patent Application No. 26535/95, dated November 24, 1999 (Attorney's Reference No. 3921-1-PAU)
	33	Supplementary European Search Report for European Application No. 95921459.4, dated April 3, 1998 (Attorney's Reference No. 3921-1-PEP)
	34	Supplementary European Search Report for European Application No. 95921459.4, dated April 22, 1999 (Attorney's Reference No. 3921-1-PEP)
	35	International Preliminary Examination Report for International (PCT) Application No. PCT/US95/06742, mailed September 3, 1996
	36	International Search Report for International (PCT) Application No. PCT/US95/06742, mailed August 5, 1995
	37	Written Opinion for International (PCT) Application No. PCT/US95/06742, mailed August 5, 1995
	38	Kang et al., "Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction," 1997, Nature Med. 3:738-743

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.